Priovant's LISRAYA Wins FDA Nod for Dermatomyositis, First New…

Event summary

FDA approves Priovant's LISRAYA (brepocitinib) for adult dermatomyositis, a rare autoimmune disease with no prior targeted therapies.
LISRAYA is the first and only TYK2/JAK1 inhibitor approved for dermatomyositis, offering steroid-sparing benefits and improved disease activity.
Approval based on the VALOR trial, the largest dermatomyositis study ever conducted, showing 55% of patients achieving moderate or better improvement.
Priovant offers a patient support program with potential $0 monthly cost for eligible patients.
LISRAYA is now available in the U.S. through a limited distribution network of specialty pharmacies.

The big picture

Priovant's FDA approval for LISRAYA marks a significant milestone in the treatment of dermatomyositis, a debilitating autoimmune disease with limited therapeutic options. The approval underscores the growing trend of targeted therapies in rare diseases, potentially reshaping the competitive landscape and patient care standards. Roivant Sciences, Priovant's parent company, continues to expand its portfolio of innovative treatments, reinforcing its position in the biotechnology sector.

What we're watching

Market Penetration: Whether Priovant can effectively reach the dermatomyositis patient population through its specialty pharmacy network and patient support program.
Therapeutic Expansion: The pace at which Priovant advances brepocitinib into other autoimmune indications, including non-infectious uveitis and cutaneous sarcoidosis.
Competitive Landscape: How existing treatments for dermatomyositis, such as steroids and IVIG, adapt to the introduction of a targeted therapy like LISRAYA.